Marianne P. Allen

Array ( [id] => 20033306 [patent_doc_number] => 20250171528 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-29 [patent_title] => ANTIBODIES TARGETING IL3 [patent_app_type] => utility [patent_app_number] => 19/033679 [patent_app_country] => US [patent_app_date] => 2025-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12318 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19033679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19969687 [patent_doc_number] => 12338279 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-24 [patent_title] => Selective and potent inhibitory antibodies of myostatin activation [patent_app_type] => utility [patent_app_number] => 18/988612 [patent_app_country] => US [patent_app_date] => 2024-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 65 [patent_figures_cnt] => 78 [patent_no_of_words] => 87873 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 287 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18988612 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20108271 [patent_doc_number] => 12358979 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-15 [patent_title] => Antibodies that bind interleukin 13 and methods of use [patent_app_type] => utility [patent_app_number] => 18/979795 [patent_app_country] => US [patent_app_date] => 2024-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 56026 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18979795 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20024918 [patent_doc_number] => 20250163140 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-22 [patent_title] => ANTI-FGF23 ANTIBODY OR ANTIBODY FRAGMENT THEREOF [patent_app_type] => utility [patent_app_number] => 18/964217 [patent_app_country] => US [patent_app_date] => 2024-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25456 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 1 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18964217 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20024918 [patent_doc_number] => 20250163140 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-22 [patent_title] => ANTI-FGF23 ANTIBODY OR ANTIBODY FRAGMENT THEREOF [patent_app_type] => utility [patent_app_number] => 18/964217 [patent_app_country] => US [patent_app_date] => 2024-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25456 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 1 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18964217 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19709311 [patent_doc_number] => 20250019453 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-16 [patent_title] => IL2RB/IL2G SYNTHETIC CYTOKINES [patent_app_type] => utility [patent_app_number] => 18/799473 [patent_app_country] => US [patent_app_date] => 2024-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47831 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18799473 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19556498 [patent_doc_number] => 20240368290 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => TMEM219 ANTIBODIES AND THERAPEUTIC USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/772062 [patent_app_country] => US [patent_app_date] => 2024-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23211 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18772062 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19658492 [patent_doc_number] => 20240425557 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-26 [patent_title] => Albumin Bound Macromolecule Tri-Agonist Activating GLP-1/GIP/Glucagon Receptors [patent_app_type] => utility [patent_app_number] => 18/753823 [patent_app_country] => US [patent_app_date] => 2024-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21953 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18753823 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19916219 [patent_doc_number] => 12291573 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-06 [patent_title] => Application of a nanobody targeting on IL-6RA [patent_app_type] => utility [patent_app_number] => 18/642478 [patent_app_country] => US [patent_app_date] => 2024-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 11 [patent_no_of_words] => 2255 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18642478 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19233747 [patent_doc_number] => 20240190939 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => TIGIT- AND LIGHT-BASED CHIMERIC PROTEINS [patent_app_type] => utility [patent_app_number] => 18/594400 [patent_app_country] => US [patent_app_date] => 2024-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30057 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18594400 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19448951 [patent_doc_number] => 20240309081 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => ANTI-HUMAN INTERLEUKIN-33 MONOCLONAL ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/593108 [patent_app_country] => US [patent_app_date] => 2024-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5844 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18593108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19389453 [patent_doc_number] => 20240279323 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => METHODS FOR THE TREATMENT OF SCLERODERMA AND RELATED CONDITIONS [patent_app_type] => utility [patent_app_number] => 18/436546 [patent_app_country] => US [patent_app_date] => 2024-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24840 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18436546 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20158212 [patent_doc_number] => 12384824 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-12 [patent_title] => Method for producing an active hepatocyte growth factor (HGF) [patent_app_type] => utility [patent_app_number] => 18/429738 [patent_app_country] => US [patent_app_date] => 2024-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 6 [patent_no_of_words] => 3160 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 160 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18429738 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19389452 [patent_doc_number] => 20240279322 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => ISOFORM-SELECTIVE ANTI-TGF-BETA ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/420510 [patent_app_country] => US [patent_app_date] => 2024-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 120870 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18420510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19631151 [patent_doc_number] => 20240409600 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-12 [patent_title] => DUAL CYTOKINE FUSION PROTEINS COMPRISING MULTI-SUBUNIT CYTOKINES [patent_app_type] => utility [patent_app_number] => 18/410568 [patent_app_country] => US [patent_app_date] => 2024-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20170 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18410568 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19512126 [patent_doc_number] => 20240343812 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => COMPOSITIONS, DOSES, AND METHODS FOR TREATMENT OF THYROID EYE DISEASE [patent_app_type] => utility [patent_app_number] => 18/391233 [patent_app_country] => US [patent_app_date] => 2023-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29443 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18391233 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19614985 [patent_doc_number] => 20240400665 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-05 [patent_title] => CROSS-SPECIES ANTI-LATENT TGF-BETA 1 ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/541602 [patent_app_country] => US [patent_app_date] => 2023-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35446 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18541602 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19464192 [patent_doc_number] => 20240317861 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => ANTIBODIES AGAINST PD-L1 [patent_app_type] => utility [patent_app_number] => 18/539509 [patent_app_country] => US [patent_app_date] => 2023-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44468 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18539509 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19067231 [patent_doc_number] => 20240101657 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => ANTIBODY THAT BINDS TO VEGF AND IL-1BETA AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/510174 [patent_app_country] => US [patent_app_date] => 2023-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34196 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18510174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19156201 [patent_doc_number] => 20240148908 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies [patent_app_type] => utility [patent_app_number] => 18/485838 [patent_app_country] => US [patent_app_date] => 2023-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34806 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18485838 [rel_patent_id] =>[rel_patent_doc_number] =>)